Intervention protocol: OPtimising thERapy to prevent avoidable hospital Admission in the Multi-morbid elderly (OPERAM): a structured medication review with support of a computerised decision support system.
Aged
Humans
Chronic Disease
/ drug therapy
Cohort Studies
Decision Support Systems, Clinical
Drug-Related Side Effects and Adverse Reactions
/ prevention & control
Hospitalization
Inappropriate Prescribing
/ prevention & control
Medication Reconciliation
/ methods
Multimorbidity
Polypharmacy
Potentially Inappropriate Medication List
Research Design
Randomized Controlled Trials as Topic
Multicenter Studies as Topic
Cluster randomised controlled trial
Geriatric patient
Inappropriate prescribing
STOPP/START
Journal
BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677
Informations de publication
Date de publication:
17 Mar 2020
17 Mar 2020
Historique:
received:
19
06
2019
accepted:
28
02
2020
entrez:
19
3
2020
pubmed:
19
3
2020
medline:
18
8
2020
Statut:
epublish
Résumé
Several approaches to medication optimisation by identifying drug-related problems in older people have been described. Although some interventions have shown reductions in drug-related problems (DRPs), evidence supporting the effectiveness of medication reviews on clinical and economic outcomes is lacking. Application of the STOPP/START (version 2) explicit screening tool for inappropriate prescribing has decreased inappropriate prescribing and significantly reduced adverse drug reactions (ADRs) and associated healthcare costs in older patients with multi-morbidity and polypharmacy. Therefore, application of STOPP/START criteria during a medication review is likely to be beneficial. Incorporation of explicit screening tools into clinical decision support systems (CDSS) has gained traction as a means to improve both quality and efficiency in the rather time-consuming medication review process. Although CDSS can generate more potential inappropriate medication recommendations, some of these have been shown to be less clinically relevant, resulting in alert fatigue. Moreover, explicit tools such as STOPP/START do not cover all relevant DRPs on an individual patient level. The OPERAM study aims to assess the impact of a structured drug review on the quality of pharmacotherapy in older people with multi-morbidity and polypharmacy. The aim of this paper is to describe the structured, multi-component intervention of the OPERAM trial and compare it with the approach in the comparator arm. This paper describes a multi-component intervention, integrating interventions that have demonstrated effectiveness in defining DRPs. The intervention involves a structured history-taking of medication (SHiM), a medication review according to the systemic tool to reduce inappropriate prescribing (STRIP) method, assisted by a clinical decision support system (STRIP Assistant, STRIPA) with integrated STOPP/START criteria (version 2), followed by shared decision-making with both patient and attending physician. The developed method integrates patient input, patient data, involvement from other healthcare professionals and CDSS-assistance into one structured intervention. The clinical and economical effectiveness of this experimental intervention will be evaluated in a cohort of hospitalised, older patients with multi-morbidity and polypharmacy in the multicentre, randomized controlled OPERAM trial (OPtimising thERapy to prevent Avoidable hospital admissions in the Multi-morbid elderly), which will be completed in the last quarter of 2019. Universal Trial Number: U1111-1181-9400 Clinicaltrials.gov: NCT02986425, Registered 08 December 2016. FOPH (Swiss national portal): SNCTP000002183. Netherlands Trial Register: NTR6012 (07-10-2016).
Sections du résumé
BACKGROUND
BACKGROUND
Several approaches to medication optimisation by identifying drug-related problems in older people have been described. Although some interventions have shown reductions in drug-related problems (DRPs), evidence supporting the effectiveness of medication reviews on clinical and economic outcomes is lacking. Application of the STOPP/START (version 2) explicit screening tool for inappropriate prescribing has decreased inappropriate prescribing and significantly reduced adverse drug reactions (ADRs) and associated healthcare costs in older patients with multi-morbidity and polypharmacy. Therefore, application of STOPP/START criteria during a medication review is likely to be beneficial. Incorporation of explicit screening tools into clinical decision support systems (CDSS) has gained traction as a means to improve both quality and efficiency in the rather time-consuming medication review process. Although CDSS can generate more potential inappropriate medication recommendations, some of these have been shown to be less clinically relevant, resulting in alert fatigue. Moreover, explicit tools such as STOPP/START do not cover all relevant DRPs on an individual patient level. The OPERAM study aims to assess the impact of a structured drug review on the quality of pharmacotherapy in older people with multi-morbidity and polypharmacy. The aim of this paper is to describe the structured, multi-component intervention of the OPERAM trial and compare it with the approach in the comparator arm.
METHOD
METHODS
This paper describes a multi-component intervention, integrating interventions that have demonstrated effectiveness in defining DRPs. The intervention involves a structured history-taking of medication (SHiM), a medication review according to the systemic tool to reduce inappropriate prescribing (STRIP) method, assisted by a clinical decision support system (STRIP Assistant, STRIPA) with integrated STOPP/START criteria (version 2), followed by shared decision-making with both patient and attending physician. The developed method integrates patient input, patient data, involvement from other healthcare professionals and CDSS-assistance into one structured intervention.
DISCUSSION
CONCLUSIONS
The clinical and economical effectiveness of this experimental intervention will be evaluated in a cohort of hospitalised, older patients with multi-morbidity and polypharmacy in the multicentre, randomized controlled OPERAM trial (OPtimising thERapy to prevent Avoidable hospital admissions in the Multi-morbid elderly), which will be completed in the last quarter of 2019.
TRIAL REGISTRATION
BACKGROUND
Universal Trial Number: U1111-1181-9400 Clinicaltrials.gov: NCT02986425, Registered 08 December 2016. FOPH (Swiss national portal): SNCTP000002183. Netherlands Trial Register: NTR6012 (07-10-2016).
Identifiants
pubmed: 32183810
doi: 10.1186/s12913-020-5056-3
pii: 10.1186/s12913-020-5056-3
pmc: PMC7076919
doi:
Banques de données
ClinicalTrials.gov
['NCT02986425']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
220Subventions
Organisme : Staatssekretariat für Bildung, Forschung und Innovation
ID : 15.0137
Organisme : Horizon 2020
ID : 634238
Références
Chest. 2010 Nov;138(5):1093-100
pubmed: 20299623
Eur J Clin Pharmacol. 2015 Oct;71(10):1255-62
pubmed: 26249851
Clin Pharmacol Ther. 2011 Jun;89(6):845-54
pubmed: 21508941
Med J Aust. 1998 Jul 20;169(2):85-8
pubmed: 9700343
Am J Geriatr Pharmacother. 2010 Apr;8(2):115-26
pubmed: 20439061
Ned Tijdschr Geneeskd. 2010;154:A904
pubmed: 20356426
BMJ. 2004 Jul 3;329(7456):15-9
pubmed: 15231615
Drugs Aging. 2016 Jan;33(1):63-73
pubmed: 26597401
Int J Clin Pharm. 2016 Apr;38(2):374-9
pubmed: 26797770
BMJ. 2010 Oct 14;341:c5146
pubmed: 20947577
Arch Intern Med. 2008 Sep 22;168(17):1890-6
pubmed: 18809816
Cochrane Database Syst Rev. 2014 Oct 07;(10):CD008165
pubmed: 25288041
Value Health. 2011 Jan;14(1):34-40
pubmed: 21211484
Drug Saf. 2012 Jan;35 Suppl 1:47-54
pubmed: 23446785
Clin Interv Aging. 2016 Jun 23;11:857-66
pubmed: 27382268
Expert Opin Drug Saf. 2014 Jan;13(1):57-65
pubmed: 24073682
Pharmacoepidemiol Drug Saf. 2003 Sep;12(6):491-8
pubmed: 14513663
J Am Geriatr Soc. 2019 Sep;67(9):1843-1850
pubmed: 31250427
Drugs Aging. 2015 Jun;32(6):495-503
pubmed: 26025118
PLoS One. 2018 Apr 18;13(4):e0195232
pubmed: 29668763
Age Ageing. 2015 Mar;44(2):213-8
pubmed: 25324330
Nephrol Dial Transplant. 2011 Oct;26(10):3176-81
pubmed: 21325352
Drugs Aging. 2009;26(8):687-701
pubmed: 19685934
Br J Clin Pharmacol. 2009 Jun;67(6):671-5
pubmed: 19594536
BMC Med. 2018 Feb 13;16(1):21
pubmed: 29433501
J Gen Intern Med. 2012 Oct;27(10):1361-7
pubmed: 22618581
J Am Geriatr Soc. 2016 Aug;64(8):1558-66
pubmed: 27365262
J Am Geriatr Soc. 2011 Oct;59(10):1976-7
pubmed: 22091519
Br J Clin Pharmacol. 2014 Oct;78(4):738-47
pubmed: 24661192
J Clin Epidemiol. 2001 Jul;54(7):680-6
pubmed: 11438408
CMAJ. 2005 Aug 30;173(5):510-5
pubmed: 16129874
BMC Geriatr. 2017 Oct 10;17(1):230
pubmed: 29017448
J Am Acad Nurse Pract. 2005 Apr;17(4):123-32
pubmed: 15819637
JAMA Intern Med. 2015 May;175(5):827-34
pubmed: 25798731
CNS Drugs. 2013 Nov;27(11):963-9
pubmed: 23959814
J Clin Hypertens (Greenwich). 2008 May;10(5):348-54
pubmed: 18453793
Age Ageing. 2018 Sep 1;47(5):670-678
pubmed: 29893779
J Eval Clin Pract. 2018 Apr;24(2):317-322
pubmed: 28776873
Emerg Med J. 2014 Jan;31(1):24-9
pubmed: 23389832
J Clin Pharm Ther. 2018 Apr;43(2):224-231
pubmed: 28971492
BMJ Open. 2019 Jun 3;9(6):e026769
pubmed: 31164366